Related Experiment Video
Updated: Jan 7, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
The Molecular Landscape and Utility of Multiomic Analyses in Triple-Negative Breast Cancer: Further Subtyping and
Conan Juan1,2, Yan Peng3
1Department of Pathology, School of Medicine, Stanford University, Palo Alto, CA 94305, USA.
Abstract:
Triple-negative breast cancer (TNBC) has the poorest prognosis among all breast cancer subtypes, largely due to the lack of targeted therapies and its resistance to both chemotherapy and immunotherapy. A deeper understanding of TNBC biology is therefore critical for identifying therapeutic targets. Molecular subtyping of TNBC, first introduced over a decade ago, has significantly advanced our knowledge of the disease's biology. However, tumor heterogeneity remains a major factor contributing to poor clinical outcomes and treatment resistance. The integration of multiomic technologies, including genomic, transcriptomic, proteomic, and metabolomic analyses, offers a powerful approach to further dissect tumor heterogeneity and accelerate the discovery of new biomarkers and therapeutic targets. This review aims to highlight the potential utility and evolving role of multiomics (-omics) in improving our understanding of TNBC biology-particularly tumor heterogeneity-ultimately facilitating the development of novel therapies and actionable strategies to treat the disease.
Insights
Triple-negative breast cancer (TNBC) is aggressive due to limited treatments. Multiomics approaches are crucial for understanding TNBC tumor heterogeneity and developing new therapies.
Area of Science:
- Oncology
- Genomics
- Proteomics
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and lack of targeted therapies.
- Tumor heterogeneity in TNBC contributes to poor prognosis and resistance to conventional treatments like chemotherapy and immunotherapy.
Purpose of the Study:
- To explore the role of multiomics technologies in understanding TNBC biology, focusing on tumor heterogeneity.
- To highlight the potential of multiomics for discovering novel biomarkers and therapeutic targets for TNBC.
Main Methods:
- Review of current literature on TNBC molecular subtyping and multiomics applications.
- Integration of genomic, transcriptomic, proteomic, and metabolomic data analysis strategies.
Main Results:
- Molecular subtyping has advanced TNBC knowledge, but heterogeneity persists as a challenge.
- Multiomics integration offers a comprehensive approach to dissecting TNBC complexity.
Conclusions:
- Multiomics are essential for a deeper understanding of TNBC tumor heterogeneity.
- This approach can accelerate the development of targeted therapies and improve treatment strategies for TNBC patients.
